Universal Rare Gene Study: A Registry and Natural History Study of Retinal Dystrophies Associated With Rare Disease-Causing Genetic Variants

Recruiting

• Conditions: Retinitis Pigmentosa; Inherited Retinal Degeneration

• Registration Number: NCT05589714
• Lead Sponsor: Jaeb Center for Health Research

Brief Summary

This is an international, multicenter study with two components:

Registry

* A standardized genetic screening and a prospective, standardized, cross-sectional clinical data collection

* Enrollment is open to all genes on the RD Rare Gene List

Natural History Study

* A prospective, standardized, longitudinal Natural History Study

* Enrollment opens gene-by-gene, based on funding and within-gene Registry enrollment The study objectives are as follows.

Registry Objectives

1. Genotype Characterization

2. Cross-Sectional Phenotype Characterization (within gene)

3. Establish a Link to My Retina Tracker Registry (MRTR)

4. Ancillary Exploratory Studies - Pooling of Genes

Natural History Study Objectives

1. Natural History (within gene)

2. Structure-Function Relationship (within gene)

3. Risk Factors for Progression (within gene)

4. Ancillary Exploratory Studies - Pooling of Genes

Detailed Description

This study includes multiple phases.

1. Screening Phase

The patient's current genetic report will be reviewed. Genetic testing will not be performed in this study. A prior conclusive genetic test will be assessed for screening analysis. Having at least one gene on the RD Rare Gene List meets one of the eligible Genetic Screening Criteria and other eligibility criteria can be evaluated based on medical history.

2. Genetic Screening Phase:

Genetic reports for participants enrolled into the genetic screening phase will be uploaded to study website for review and confirmation by Central Genetics Auditor (CGA) as meeting Genetic Screening Criteria.Participants confirmed as meeting those criteria will be considered enrolled into the Registry.

3. Registry Phase:

The flow of participants who are enrolled into the Registry depends on whether their causal gene is designated as a Natural History Study (NHS) Target Gene. If they are not Designated as NHS Target Gene, they will receive annual phone calls up to 48 months from the Registry/Screening visit or until the gene is designated as NHS Target Gene. If they are Designated as NHS Target Gene participants will be considered pending enrollment into the NHS.

The Registry will establish genetically and clinically well-characterized cohorts of patients across hundreds of genetic variants associated with retinal dystrophy (RD). Characterization of these patients will accelerate eligibility screening for the Natural History Study, provide cross-sectional data on phenotype-genotype associations, and contribute to our knowledge of pathogenicity of these rare disease-causing variants.

4. Natural History Study (NHS) Phase

Participants pending enrollment will return to the clinic for the NHS Enrollment/Baseline Visit and return to the clinic for follow-up visits.

The Natural History Study will accelerate the identification and development of sensitive, reliable outcome measures for clinical trials, which will facilitate development of treatments for retinal dystrophies due to disease-causing genetic variants. The expected impact of the Natural History Study is as follows:

1. Describe the natural history of retinal degeneration in patients with rare disease-causing genetic variants

2. Identify sensitive structural and functional outcome

3. Identify well-defined subpopulations for future clinical trials of investigative treatments for rare inherited retinal degeneration

Study Timeline

• Study First Submitted: 2022-10-18
• Study First Submitted QC: 2022-10-18
• Study First Posted: 2022-10-21
• Study Start: 2023-05-11
• Status Verified: 2024-05
• Last Update Submitted: 2025-02-07
• Last Update Posted: 2025-02-10
• Primary Completion: 2028-12-15
• Study Completion: 2028-12-15

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 1500

Inclusion Criteria

Participants must meet all the following inclusion criteria at the Registry/Screening Visit to be eligible to enroll into the genetic screening phase:

1. Willing to participate in the study and able to communicate consent during the consent process
2. Willing and able to complete all applicable Registry/Screening Visit assessments
3. Age ≥ 4 years
4. Must have a single gene on the RD Rare Gene List which meets one of the Genetic Screening Criteria below based on a genetic report* from a clinically certified lab (or from a research lab which has been approved by the study Genetics Committee):

Inheritance Pattern is Recessive and has at least 2 disease-causing variants which are homozygous or heterozygous in trans

OR

Inheritance Pattern is Recessive and has 2 disease-causing variants with unknown phase and meets all the following additional informatic criteria that is consistent with likely segregation in trans:

1. Investigator confirms genotype and phenotype are consistent with autosomal recessive inheritance
2. The 2 disease-causing variants have not been reported in cis in variant databases
3. No additional potentially pathogenic variants were found on the gene (and the sequencing data for the gene were sufficiently robust to detect any additional potentially pathogenic variants)
4. No potentially pathogenic variants were found in other common, likely candidate genes for the proposed condition

OR

Inheritance Pattern is Dominant, X-linked, or Mitochondrial and has at least 1 disease-causing variant

Both eyes must meet the following criteria at the Registry/Screening Visit to enroll into the genetic screening phase:

1. Both eyes must have a clinical diagnosis of retinal dystrophy
2. Both eyes must permit good quality photographic imaging (e.g., but not limited to, clear ocular media, adequate pupil dilation, stable fixation)

Exclusion Criteria

Participants must not meet any of the following exclusion criteria at the Registry/Screening Visit to be eligible to enroll into the genetic screening phase:

1. History of more than 1 year of cumulative treatment, at any time, with an agent associated with pigmentary retinopathy including amiodarone, chloroquine, deferoxamine, hydroxychloroquine, pentosan polysulfate, tamoxifen, and deferoxamine Note: Since this is an observational study, pregnant women will not be specifically excluded from participation. However, minors that are pregnant shall be precluded from participation until they become the age of majority.

Ocular Exclusion Criteria:

If either eye has any of the following ocular exclusion criteria at the Registry/Screening Visit, then the participant is not eligible to enroll into the genetic screening phase:

1. Current vitreous hemorrhage

2. Current complications of pathological myopia (for example, but not limited to, myopic maculopathy including atrophy, scar, choroidal neovascularization, schisis) that could inhibit ability to obtain good quality photographic imaging

3. History of intraocular surgery (for example, but not limited to, cataract surgery, vitrectomy, penetrating keratoplasty, or LASIK) within 3 months of Registry/Screening Visit

4. Current or any history of confirmed diagnosis of glaucoma (for example, but not limited to, glaucomatous VF changes or nerve changes, or history of glaucoma filtering surgery)

5. Current or any history of retinal vascular occlusion or proliferative diabetic retinopathy

6. History or current evidence of ocular disease that, in the opinion of the Investigator, may confound assessment of visual function (for example, but not limited to, tractional or rhegmatogenous retinal detachment, any vitreoretinal surgery, retinal vascular occlusion, proliferative diabetic retinopathy)

7. The following medications and treatments are prohibited as they can affect progression of retinitis pigmentosa (RP). The participant must not have received the following treatments:

   Any use of ocular stem cell or gene therapy Any treatment with ocriplasmin Treatment with Ozurdex (dexamethasone), Iluvien, or Yutiq (fluocinolone acetonide) intravitreal implant

8. The following medications and treatments are excluded within the specified timeframe:

Treatment with an ophthalmic oligonucleotide within the last 9 months (last treatment date is less than 9 months prior to Registry/Screening Visit date)

Treatment with any other product within five times the expected half-life of the product (time from last treatment date to Registry/Screening Visit date is at least 5 times the half-life of the given product)

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Functional Outcome: Characterize Change Using Early Treatment of Diabetic Retinopathy Study (ETDRS) / HOTV Best Corrected Visual Acuity (BCVA) letter score	Baseline and every year until study completion (4 years)	Measured by Electronic Visual Acuity (EVA) system or ETDRS/HOTV charts
Functional Outcome: Characterize Change Using ETDRS/HOTV best corrected low luminance visual acuity letter score	Baseline and every year until study completion (4 years)	Measured by Electronic Visual Acuity (EVA) system or ETDRS/HOTV charts
Functional Outcome: Characterize Change in Contrast sensitivity function	Baseline and every year until study completion (4 years)	Measured by Contrast sensitivity CSV-1000E chart
Functional Outcome: Characterize Change in Full-field retinal sensitivity	Baseline and every year until study completion (4 years)	Measured by Full-field stimulus threshold (FST) testing to blue, white, and red stimuli using Diagnosys Espion
Functional Outcome: Characterize Change in Color vision function	Baseline and every year until study completion (4 years)	Measured by Color vision testing using Lanthony D15
Functional Outcome: Characterize Change in Retinal function using amplitudes and timing in response to rod- and cone-specific stimuli	Baseline and at study completion (4 years)	Measured by Full-field Electroretinogram (ffERG) Diagnosys Espion
Structural Outcome: Characterize Change in Ellipsoid zone (EZ) area; outer nuclear layer and ganglion cell layer thicknesses	Baseline and every year until study completion (4 years)	Measured by Spectral Domain Optical Coherence Tomography (SD-OCT) using Heidelberg Spectralis
Functional Outcome: Characterize change using Visual field sensitivity measured with quantitative topographic analysis (hill of vision [HOV])	Baseline and every year until study completion (4 years)	Measured by Static Perimetry (SP) using Octopus 900 Pro
Functional Outcome: Characterize Change Using Low visual acuity test - for participants unable to see ETDRS letters	Baseline and every year until study completion (4 years)	Measured by Berkeley Rudimentary Vision Test (BRVT) for Low Visual Acuity
Functional Outcome: Characterize Change in Mean retinal sensitivity	Baseline and every year until study completion (4 years)	Measured by Fundus guided Microperimetry (MP) using MAIA
Structural Outcome: Characterize Change Using Qualitative and quantitative assessments of autofluorescence pattern	Baseline and every year until study completion (4 years)	Measured by Fundus Autofluorescence (FAF) using Optos

Trial Locations

Locations (35)

University of Florida Health Jacksonville; 🇺🇸 Jacksonville, Florida, United States

Johns Hopkins University, Wilmer Eye Institute; 🇺🇸 Baltimore, Maryland, United States

University of Miami, Bascom Palmer Eye Institute; 🇺🇸 Miami, Florida, United States

University of Michigan, Kellogg Eye Center; 🇺🇸 Ann Arbor, Michigan, United States

Duke University, Duke Eye Center; 🇺🇸 Durham, North Carolina, United States

Retina Foundation of the Southwest; 🇺🇸 Dallas, Texas, United States

University of Alberta and Alberta Health Services; 🇨🇦 Edmonton, Alberta, Canada

Centre for Eye Research Australia; 🇦🇺 East Melbourne, Victoria, Australia

Helsinki University Hospital; 🇫🇮 Helsinki, Finland

Hadassah-Hebrew University Medical Center; 🇮🇱 Jerusalem, Israel

Retina and Genomics Institute; 🇲🇽 Yucatan, Merida, Mexico

Radboud University Medical Center; 🇳🇱 Nijmegen, Netherlands

University of Arkansas, Jones Eye Institute; 🇺🇸 Little Rock, Arkansas, United States

USC Roski Eye Institute; 🇺🇸 Los Angeles, California, United States

University of California San Francisco; 🇺🇸 San Francisco, California, United States

Emory University, Emory Eye Center; 🇺🇸 Atlanta, Georgia, United States

Oregon Health & Science Univ., Casey Eye Institute; 🇺🇸 Portland, Oregon, United States

INRET Clínica e Centro de Pesquisa; 🇧🇷 Belo Horizonte, Minas Gerais, Brazil

University Hospital Basel; 🇨🇭 Basel, Basel-Stadt, Switzerland

University Hospital Jules-Gonin; 🇨🇭 Lausanne, Switzerland

Harvard Univ., Massachusetts Eye and Ear Infirmary; 🇺🇸 Boston, Massachusetts, United States

Mayo Clinic; 🇺🇸 Rochester, Minnesota, United States

Center for Advanced Retinal and Ocular Therapeutics; 🇺🇸 Philadelphia, Pennsylvania, United States

University of Pennsylvania, Scheie Eye Institute; 🇺🇸 Philadelphia, Pennsylvania, United States

Baylor College of Medicine, Alkek Eye Center; 🇺🇸 Houston, Texas, United States

University of Utah, John Moran Eye Center; 🇺🇸 Salt Lake City, Utah, United States

University of Wisconsin Madison; 🇺🇸 Madison, Wisconsin, United States

Instituto de Genética Ocular; 🇧🇷 São Paulo, São Paulo Province, Brazil

University Health Network; 🇨🇦 Toronto, Canada

Vista Vision Eye Clinic; 🇮🇹 Brescia, Italy

Moorfields Eye Hospital; 🇬🇧 London, United Kingdom

UPMC Eye Center; 🇺🇸 Pittsburgh, Pennsylvania, United States

Medical College of Wisconsin Eye Institute; 🇺🇸 Milwaukee, Wisconsin, United States

University of Toronto, Hospital for Sick Children; 🇨🇦 Toronto, Ontario, Canada

CHNO des Quinze-Vingts; 🇫🇷 Paris, France